Silverback Therapeutics, Inc. (NASDAQ:SBTX - Get Free Report)'s share price traded down 6.9% during mid-day trading on Monday . The stock traded as low as $11.89 and last traded at $11.92. 1,370,275 shares traded hands during trading, an increase of 305% from the average session volume of 337,931 shares. The stock had previously closed at $12.80.
Silverback Therapeutics Trading Up 2.5 %
The company has a market capitalization of $429.81 million, a price-to-earnings ratio of -4.93 and a beta of 0.60. The company's 50 day simple moving average is $12.15 and its 200-day simple moving average is $13.06.
About Silverback Therapeutics
(
Get Free Report)
Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.
Read More
Before you consider Silverback Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Silverback Therapeutics wasn't on the list.
While Silverback Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
